---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002703"
form_type: "8-K"
ticker: "ALUR"
cik: "0001964979"
company_name: "ALLURION TECHNOLOGIES, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:39:28.874578+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Allurion prelim 2023 rev $53-54M, cuts 30% staff, 2024 outlook $60-65M

## Summary
- Full-year 2023 revenue expected $53-54M; gross margin 77-78%; procedural volume up 30% YoY.
- Q4 2023 revenue expected $8.1-8.3M; European procedural volume grew 44% in Q4 vs prior year.
- Cash balance $38M as of Dec 31, 2023; Q4 cash burn $22M; term loan reduced by $20M to $40M.
- Reduced headcount ~30% since Dec 2023 to cut quarterly cash burn to $7-8M in 2024.
- 2024 outlook: revenue $60-65M, procedural volume growth ~20%, gross margins 77-79%; FDA pivotal trial readout (AUDACITY) expected by year-end.

## SEC filing metadata
- accession: 0000950170-24-002703
- form_type: 8-K
- ticker: ALUR
- cik: 0001964979
- company_name: ALLURION TECHNOLOGIES, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/alur-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002703
- JSON: https://secwatch.observer/filing/0000950170-24-002703.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002703.txt

## Key facts
- Earnings Releases
  ALLURION TECHNOLOGIES, INC. reported the fiscal year ended December 31, 2023 results: revenue $53 - $54 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $53 - $54 million
  - Result: preliminary results
  source text: 2023 full year revenue is expected to be in the range of $53 - $54 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm
- Earnings Releases
  ALLURION TECHNOLOGIES, INC. reported the quarter ended December 31, 2023 results: revenue $8.1 - $8.3 million.
  - Period: the quarter ended December 31, 2023
  - Revenue: $8.1 - $8.3 million
  - Result: preliminary results
  source text: Fourth quarter revenue is expected to be in the range of $8.1 - $8.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm
- Earnings Releases
  ALLURION TECHNOLOGIES, INC. reported fiscal year 2024 results: revenue $60 - $65 million. Guidance initiated.
  - Period: fiscal year 2024
  - Revenue: $60 - $65 million
  - Guidance: initiated
  - Result: guidance update
  source text: 24 Outlook • Anticipated procedural volume growth of approximately 20%, despite a reduction in overall marketing spend, reflecting increased penetration in key direct markets and reallocation of marketing spend to more efficient channels • Revenue guidance of $60 - $65 million , reflecting growth of approximately 13% - 23% year over year • Expected gross margins of 77-79%, reflecting durable pricing of our gastric balloon as well as initial commercialization efforts of the digital platform • Targeted cash burn reduced to approximately $7 - $8 million per quarter Key 2024 Growth Catalysts • Accelerated procedure volume growth across direct markets where Allurion has fully established direct sales and support models • Release of new clinical data, including the AUDACITY FDA pivotal trial read-out expected by end of year, and additional data validating Allurion’s best-in-class weight loss a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1964979/000095017024002703/0000950170-24-002703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.